Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is click here experiencing substantial resistance from PBMs. The companies are often creating barriers to coverage, such as high price restrictions and approval processes that hinder patient opportunity. Analys